ConductScience.org, home

Paper98109

In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.

Yoshikawa TT and 1 other. Antimicrob Agents Chemother, 1978. Cited by 17 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa. Papers, record 98109. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/98109

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro antibacterial activity of amikacin and ticarcillin, alone and in combination, against Pseudomonas aerurginosa.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
0.65
iCite
Revised in PubMed
2021-05-26
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yoshikawa TTT T
2Shibata SAS A

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmikacinMajor topic
KanamycinMajor topic
PenicillinsMajor topic
Pseudomonas aeruginosaMajor topic
TicarcillinMajor topic
Drug Interactions
Microbial Sensitivity Tests

Source PubMed

References11

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11,096,809Empiric therapy for cancer patients: comparative study of ticarcillin-tobramycin, ticarcillin-cephalothin, and cephalothin-tobramycin.Antimicrob Agents Chemother1975https://conductscience.org/library/papers/1096809PubMed
21,190,752Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin.Antimicrob Agents Chemother1975https://conductscience.org/library/papers/1190752PubMed
3335,967Amikacin and cephalothin: empiric regimen for granulocytopenic cancer patients.Antimicrob Agents Chemother1977https://conductscience.org/library/papers/335967PubMed
4406,837Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo.Antimicrob Agents Chemother1977https://conductscience.org/library/papers/406837PubMed
54,157,342Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa.Antimicrob Agents Chemother1974https://conductscience.org/library/papers/4157342PubMed
64,201,634Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center.Ann Intern Med1973https://conductscience.org/library/papers/4201634PubMed
74,994,878Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia.N Engl J Med1971https://conductscience.org/library/papers/4994878PubMed
8586,099Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.Am J Med1977https://conductscience.org/library/papers/586099PubMed
9806,263BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa.Antimicrob Agents Chemother1975https://conductscience.org/library/papers/806263PubMed
10816,250Emergence of gentamicin- and carbenicillin-resistant Pseudomonas aeruginosa in a hospital environment.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/816250PubMed
11825,022Synergism of cefazolin-gentamicin against enterococci.Antimicrob Agents Chemother1976https://conductscience.org/library/papers/825022PubMed

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
26,031,965Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.Curr Infect Dis Rep2015https://conductscience.org/library/papers/26031965PubMed
24,184,742An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Virulence2014https://conductscience.org/library/papers/24184742PubMed
22,763,634Combination therapy for treatment of infections with gram-negative bacteria.Clin Microbiol Rev2012https://conductscience.org/library/papers/22763634PubMed
7,002,527Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.Drugs1980https://conductscience.org/library/papers/7002527PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/98109

GET https://conductscience.org/api/papers/v1/98109/authors